D. CONN.Litigation
States seek approval of $1.05M generic drug price-fixing settlements with Ascend, Mayne and Citron
Forty-eight states and territories asked the U.S. District Court for the District of Connecticut on Oct. 8 to preliminarily approve generic drug price-fixing settlements with Ascend Laboratories, Mayne Pharma and Citron Pharma, according to the states' motion. Ascend will pay $400,000 and Mayne $650,000; Citron, which ceased operations, agreed to non-monetary injunctive and cooperation terms. Connecticut's attorney general said the first trial is set for February 2027 in Hartford.
Motion (Connecticut Office of the Attorney General) → · Law360, WABI TV
Key points
- The Plaintiff States' motion was filed in the District of Connecticut in Nos. 3:16-cv-02056, 3:19-cv-00710 and 3:20-cv-00802.Connecticut Office of the Attorney General
- Ascend agreed to pay $400,000 and Mayne $650,000; Citron, which ceased operations in 2016, agreed to non-monetary terms.Connecticut Office of the Attorney GeneralConnecticut Office of the Attorney GeneralLaw360
- All three agreed to compliance reforms and cooperation; Ascend will provide up to two trial witnesses and Mayne will facilitate testimony.Connecticut Office of the Attorney General
- The proposed settlements designate Huntington Bank as escrow agent and Rust Consulting as notice and claims administrator.Connecticut Office of the Attorney General
- Connecticut's attorney general said prior settlements in the litigation total $496.5 million and the first trial is set for Hartford in February 2027.Connecticut Office of the Attorney GeneralWABI TV
Sources4 articles across 3 outlets
Connecticut Office of the Attorney General
Law360
WABI TV